Aripiprazole Efficacy and Safety Profile

Mechanism and Sedation Profile

Other antipsychotics, particularly "low-potency" agents like chlorpromazine and thioridazine, are more sedating due to their stronger anticholinergic and antihistaminic effects, according to the American College of Emergency Physicians 1

The combination of clozapine with aripiprazole has shown the lowest risk of psychiatric hospitalization (HR 0.86, 95% CI 0.79–0.94) compared to clozapine monotherapy, as recommended by the American Psychiatric Association 2
For first-episode patients, this combination showed even better outcomes (HR 0.78, 95% CI 0.63–0.96), according to the National Institute of Mental Health 2
Aripiprazole augmentation specifically improves negative symptoms (standardized mean difference −0.41, 95% CI −0.79 to −0.03, p = 0.036), as reported by the American Medical Association 3

For treatment-resistant schizophrenia, consider clozapine monotherapy first, then augment with aripiprazole if partial response or metabolic concerns arise, as suggested by the American Psychiatric Association 4
This combination shows the best outcomes for reducing hospitalization risk, according to the National Institute of Mental Health 2
For patients with specific comorbidities, aripiprazole may be preferred due to its minimal metabolic impact, as recommended by the American Diabetes Association 5

The American College of Psychiatry recommends Clozapin-Augmentation with Aripiprazol for patients with persistent positive symptoms, as stated by the international guidelines (2025) 6

Aripiprazol augmentation improves specific negative symptoms (standardized mean difference −0,41, 95% CI −0,79 bis −0,03, p = 0,036) in patients with treatment-resistant schizophrenia, as recommended by the international guidelines (2025) 6

Aripiprazol offers additional benefits in reducing Clozapin-induced side effects, including reduction of hyperprolactinemia and sexual dysfunction, as reported in the medical literature 7

The algorithm for Clozapin augmentation recommends optimizing Clozapin monotherapy by aiming for a plasma level of at least 350 ng/mL, and considering Aripiprazol augmentation with 5-15 mg/Day in case of persistent symptoms, as stated in the international guidelines (2025) 6

Die Kombination von Clozapin mit partiellen D2-Agonisten wird generell unterstützt, aber Aripiprazol hat die robusteste Datenlage, laut dem American College of Clinical Pharmacology 8
Viele Patienten tolerieren die Rückkehr zur Monotherapie gut, was darauf hindeutet, dass Polypharmazie möglicherweise zu häufig oder zu lange eingesetzt wird, wie in der Literatur von Drugs 2021 beschrieben 8
Bei Clozapin-Intoleranz sollte ein Wechsel zurück zur Monotherapie mit einem anderen Antipsychotikum erwogen werden, basierend auf den Empfehlungen von Drugs 2021 8